US 12,138,307 B2
Saponin extraction
Ahmad Taimour Baig, Hamilton, MT (US); Juan Jose Diaz Garcia, Marietta, PA (US); Chad Austin Farrenburg, Hamilton, MT (US); Kent Raymond Myers, Hamilton, MT (US); Jeri Kay Sandvick, Hamilton, MT (US); and Jeb Yeatts Vandenburg, Hamilton, MT (US)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Jul. 17, 2023, as Appl. No. 18/353,172.
Application 18/353,172 is a division of application No. 16/768,416, granted, now 11,744,890, previously published as PCT/EP2018/083233, filed on Nov. 30, 2018.
Claims priority of provisional application 62/593,555, filed on Dec. 1, 2017.
Claims priority of application No. 17209796 (EP), filed on Dec. 21, 2017.
Prior Publication US 2023/0355752 A1, Nov. 9, 2023
Int. Cl. A61K 36/00 (2006.01); A61K 36/185 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 36/185 (2013.01); A61K 2039/55577 (2013.01); A61K 2236/331 (2013.01)] 42 Claims
 
1. A composition comprising a crude aqueous extract of Quillaja saponaria Molina and an exogenous antimicrobial agent; the crude aqueous extract of Quillaja saponaria Molina comprising a QS-21 main peak and a 2018 component; the composition having a 2018 component: QS-21 main peak ratio of less than or equal to 0.075:1; and the 2018 component: QS-21 main peak ratio being a peak area of the 2018 component, as measured by absorbance of ultraviolet (UV) light at a wavelength of 214 nm, to the peak area of the QS-21 main peak, as measured by absorbance of UV light at the wavelength of 214 nm.